Welcome to your one-stop gateway

to public funding in the life sciences sector

How we help you

BJY Advice offers innovators in the life sciences tailored support to secure public funding as a strategic lever for investment in R&D, production facilities, skills development and sustainability.

Our guiding principle is to save you time and secure public funding to speed up your innovations and boost your growth.

Our expertise at your service

Funding strategy

BJY Advice supports you to:

formalise, organise and prioritise your innovation ideas,
connect with the right stakeholders within the innovation ecosystem,
select the public funding schemes best suited to your needs,
combine these sources of funding to optimise your innovation expenses,
Build a strategic roadmap to fund your innovation pipeline.

Project management

BJY Advice supports you step by step with the technical, financial, legal, and administrative design of your innovation projects, whether for preparing your grant applications or implementing your awarded projects.

What our clients say about us

Benoît-Jules played a pivotal role in structuring the QUANTICARDI project (FUI, 2011), which aimed to develop a strontium‑82 production process, a strontium‑82/rubidium‑82 generator, and an associated injector for cardiac imaging, in order to predict cardiovascular risk and adapt treatment accordingly. He effectively coordinated the technological development that subsequently enabled us to complete all the stages leading to marketing authorisation for the strontium‑82/rubidium‑82 generator in 2024 by NaoGen Pharma, a spin‑off from the QUANTICARDI project. He also demonstrated exceptional personal commitment in the preparation and follow-up of our “GO‑Radiopharma” application under the French Recovery Plan in 2020 for the industrialisation phase of the generator. The quality of his advice and the time he devoted, without ever counting it, to supporting me as CEO responsible for financing enabled NaoGen Pharma to become a “Recovery Plan award‑winning company” in 2021. Securing this status gave us access to a €1.5 million government grant and significantly strengthened our profile with private and institutional investors such as the Regional Council, Bpifrance and regional banks, who then played a major role in providing the additional non-dilutive financing that followed recognition of our status as a “government‑backed company”.

Sylvain FANIER, Président

Thanks to Benoît-Jules’ support, Biowest successfully secured funding under the France Relance program. His expertise in project management, combined with a rigorous methodology and a clear strategic vision, was instrumental in preparing an application that was both robust and convincing.

Samuel BOUTIN, Président

Benoît-Jules helped us secure several public grants, most recently France 2030. He has extensive experience with calls for proposals in Pays de la Loire, as well as at national and European level. His approach is methodical, ensuring that both the requirements and ambitions of each call are fully addressed.

Tuan Huy NGUYEN, President

OSE Immunotherapeutics is a biotechnology company that develops first-in-class products in immuno-oncology and immuno-inflammation. The company had the opportunity to be supported by Benoît-Jules in order to optimise the funding of its innovative projects. Through an in-depth review of our programmes, he helped us select the most competitive projects and the most suitable funding schemes.

Nicolas POIRIER, Chief Scientific Officer

Affilogic discovers and develops biotherapeutics based on small affinity proteins, Nanofitins®, and has invested more than €5 million in a new Nanofitin® production facility in Nantes, with the support of the Pays de la Loire Region and the French State under the France Relance plan.

Olivier KITTEN, President

Benoît-Jules was able to understand our project to create a surgical training centre (SKLYLAB) and identify the most suitable public funding programme. He guided us throughout the drafting of the project, refocusing our presentation to meet the expectations of the evaluators.

Thibaud POUJADE, Chief Executive Officer

We had the opportunity to work with Benoît-Jules on our innovation project, for which we obtained funding from Bpifrance. From the outset, Benoît-Jules provided us with valuable expertise, guiding us at every stage in choosing the most appropriate funding, structuring our presentation, shaping our arguments, and building our application.

Fabrice PICARD, Chief Executive Officer

I had the pleasure of working with Benoît-Jules on a complex grant application project submitted to the French State under the “Industrialisation et Capacités Santé 2030” call for projects of the France 2030 investment plan. I was able to appreciate his great professionalism, attention to detail, and extensive experience, which proved essential to the success of the project.

Lucio LAVACCHIELLI, President

I can only recommend our collaboration with Benoît-Jules, which enabled us to streamline the presentation of our TECTONICS project and clarify the missing elements needed to obtain funding under the Concours d’innovation i-Nov call for projects.

Jean-Pierre PODGORSKY, President

Benoît-Jules brought real added value to our industrial site modernisation project (ORTHOPROD5.0) thanks to his methodical approach and his thorough understanding of the specific challenges in our sector. His support enabled us to structure a clear and compelling application that fully met the requirements of the “Industrialisation et Capacités Santé – France 2030” call for projects.

Eric LEROUX, Industrial Director

Benoît-Jules played a key role in building the Train4Bioprod project, in response to the “Compétences et Métiers d’Avenir” call for projects under the France 2030 programme. This project was selected in December 2024 and received €3.5 million in funding.

Jean-Marie BACH, Deputy Director

Benoît-Jules’ contribution was essential to the success of the Quanticardi® project. From the very first funding applications, he managed to bring together the energies of a consortium made up of partners from diverse cultures and backgrounds, never losing sight of the ultimate goal of bringing the project to market.